We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
173 result(s) found, displaying 1 to 10
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Oct-2024Prescription medicine evaluationActive ingredient: nivolumab.
-
Australian Public Assessment Report (AusPAR)Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, has been approved for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.
-
Sep-2024Prescription medicine evaluationActive ingredient: Ipilimumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: nivolumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: Ipilimumab.
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
May-2024Prescription medicine evaluationActive ingredient: repotrectinib.
-
Mar-2024Prescription medicine evaluationActive ingredient: nivolumab.